Why Did Warren Buffett Buy Amazon Stock?
When investors think of tech stocks in Warren Buffett’s portfolio,…
Sell
40
BIOA Quote, Financials, Valuation and Earnings
Last price:
$4.33
Seasonality move
:
--
Day range:
$4.18 - $4.47
52-week range:
$2.88 - $26.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.50x
Volume:
444.3K
Avg. volume:
295.1K
1-year change:
--
Market cap:
$155.6M
Revenue:
--
EPS (TTM):
-$8.05
Analysts' Opinion
-
Consensus RatingBioage Labs has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 3 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $6.00, Bioage Labs has an estimated upside of 38.25% from its current price of $4.34.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $4.34.
Fair Value
-
According to the consensus of 4 analysts, Bioage Labs has 38.25% upside to fair value with a price target of $6.00 per share.
BIOA vs. S&P 500
-
Over the past 5 trading days, Bioage Labs has underperformed the S&P 500 by -3.19% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bioage Labs does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bioage Labs has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Bioage Labs reported revenues of $1.5M.
Earnings Growth
-
Bioage Labs has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Bioage Labs reported earnings per share of -$0.36.
Enterprise value:
-157.9M
EV / Invested capital:
-0.49x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
2.92x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-1133.43%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $1.5M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -$49.7M | -$81.8M | -$12.8M | -$16.4M | |
| EBITDA | -- | -$57.4M | -$69.5M | -$11.7M | -$12.6M | |
| Diluted EPS | -- | -$3.00 | -$8.05 | -$0.38 | -$0.36 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $178.8M | $324.8M | |
| Total Assets | -- | -- | -- | $179.6M | $343.8M | |
| Current Liabilities | -- | -- | -- | $15.1M | $23.7M | |
| Total Liabilities | -- | -- | -- | $365.1M | $30.7M | |
| Total Equity | -- | -- | -- | -$185.5M | $313.2M | |
| Total Debt | -- | -- | -- | -- | $7.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$43M | -$53.2M | -$15.7M | -$17.4M | |
| Cash From Investing | -- | -$155K | -$78.4M | -- | -$78M | |
| Cash From Financing | -- | $179.4M | $211.7M | $168M | -$1.5M | |
| Free Cash Flow | -- | -$43.2M | -$54M | -$15.7M | -$17.8M | |
BIOA
Sector
Market Cap
$155.6M
$32.8M
Price % of 52-Week High
16.3%
46.28%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
--
-35.38%
Beta (5-Year)
--
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.41
200-day SMA
Buy
Level
$0.00
Bollinger Bands (100)
Buy
Level
3.79 - 4.61
Chaikin Money Flow
Sell
Level
-6.2M
20-day SMA
Buy
Level
$4.24
Relative Strength Index (RSI14)
Buy
Level
55.01
ADX Line
Buy
Level
16.15
Williams %R
Neutral
Level
-46.7532
50-day SMA
Buy
Level
$4.08
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
859.7K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
Stock Forecast FAQ
In the current month, BIOA has received 0 Buy ratings 3 Hold ratings, and 1 Sell ratings. The BIOA average analyst price target in the past 3 months is $6.00.
-
Where Will Bioage Labs Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bioage Labs share price will rise to $6.00 per share over the next 12 months.
-
What Do Analysts Say About Bioage Labs?
Analysts are divided on their view about Bioage Labs share price and where it will be in the next 12 months. The majority of analysts rate the stock a Sell. However, a smaller subset of analysts suggest that Bioage Labs is a Buy and believe this share price will drop from its current level to $10.00.
-
What Is Bioage Labs's Price Target?
The price target for Bioage Labs over the next 1-year time period is forecast to be $6.00 according to 4 Wall Street analysts, 0 of them rate the stock a Buy, 1 rates the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is BIOA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bioage Labs is a Hold. 3 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BIOA?
You can purchase shares of Bioage Labs via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bioage Labs shares.
-
What Is The Bioage Labs Share Price Today?
Bioage Labs was last trading at $4.33 per share. This represents the most recent stock quote for Bioage Labs. Yesterday, Bioage Labs closed at $4.34 per share.
-
How To Buy Bioage Labs Stock Online?
In order to purchase Bioage Labs stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will RocketLab Stock Be In 5 Years?
Rocket Lab (NASDAQ: RKLB) closed recently at around $30 per share,…
Is MO dividend Worth It?
Altria Group (NYSE: MO) is paying investors $1.02 a share…
Stock Ideas
Buy
64
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
83
GMS alert for Jun 23
GMS [GMS] is up 0.03% over the past day.
Buy
54
SMLR alert for Jun 23
Semler Scientific [SMLR] is up 16.13% over the past day.
Buy
57
GXO alert for Jun 23
GXO Logistics [GXO] is up 2.42% over the past day.
